$184.87
▲ +1.0% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 2
● 20
▼ 0
Better Growth Buy: Axsome vs Revolution Medicines
Revolution Medicines Says Pancreatic Cancer Drug Candidate Daraxonrasib Under EMA Phased Review
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Overview
52-week range
$34
$166
100% of range
Avg surprise (last 3)
-21.8%
Avg reaction (last 2)
+1.6%
100% positive
Latest IV / EM
54%
EM ±12.3% · $185 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-2.29 | $-1.83 | -25.1% | -102.7% | +2.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.61 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-1.31 | $-0.94 | -39.4% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-1.13 | $-1.12 | -0.9% | — | +0.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.94 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.70 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.99 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.92 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$1.92 | -$1.31 | -46.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-445M | — | $-315M | $-265M | $-241M | — | $-176M | $-157M |
| Net income | $-454M | — | $-305M | $-248M | $-213M | — | $-156M | $-133M |
| EPS (diluted) | $-2.29 | — | $-1.61 | $-1.31 | $-1.13 | — | $-0.94 | $-0.81 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $441M | $384M | $217M | $402M | $334M | $543M | $201M | $276M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B | $1.62B |
| Total assets | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B | $1.81B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $754M | $723M | $655M | $564M | $287M | $293M | $197M | $190M |
| Total equity | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B | $1.62B |